A downtrend has been apparent in SelectQuote (SLQT) lately with too much selling pressure. The stock has declined 27% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. Th ...

Timothy Robert Danker: Thanks, Matt. Good morning, and thank you for joining us. It was a strong quarter for SelectQuote in a number of ways, which I'll summarize on slide three. As you saw from our press release, our team's execution this Medicare Advantage season drove a successful AEP. Despite another shifting backdrop for policy features, SelectQuote continues to prove its value to customers as the leading choice marketplace. As always, seniors received bespoke information and assistance from live agent ...

SelectQuote (NYSE:SLQT) Q2 2026 Earnings call February 05, 2026 08:00 AM ET Company ParticipantsBen Hendrix - VPBob Grant - PresidentDavid Windley - Managing DirectorMatt Gunter - Head of Investor RelationsRyan Clement - CFOTim Danker - CEOConference Call ParticipantsGeorge Sutton - Senior Research AnalystPat McCann - Equity Research AnalystOperatorWelcome to SelectQuote's Q2 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will ...

SelectQuote (NYSE:SLQT) Q2 2026 Earnings call February 05, 2026 08:00 AM ET Company ParticipantsBen Hendrix - VPBob Grant - PresidentDavid Windley - Managing DirectorMatt Gunter - Head of Investor RelationsRyan Clement - CFOTim Danker - CEOConference Call ParticipantsGeorge Sutton - Senior Research AnalystPat McCann - Equity Research AnalystOperatorWelcome to SelectQuote's second quarter earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks ...

Policy Submissions and Approvals - Total submitted policies for all products increased by 1% for the three months ended December 31, 2025, compared to the same period in 2024, primarily due to a 7% increase in the number of average productive agents[185]. - Total approved policies for all products increased by 4% for the three months ended December 31, 2025, compared to the same period in 2024, correlating with the increase in submitted policies[190]. - Medicare Advantage plans accounted for 93% of approved Senior policies for the three months ended December 31, 2025, consistent with the previous year[178]. - Total approved policies decreased by 5% for the six months ended December 31, 2025, compared to the same period in 2024, correlating with the decrease in submitted policies[191]. Membership and Growth - The total number of SelectRx members increased by 17% as of December 31, 2025, compared to December 31, 2024, reflecting the company's strategy to grow SelectRx membership[197]. - Average prescriptions shipped per day increased to 32,578 for the three months ended December 31, 2025, compared to 26,846 for the same period in 2024[198]. - The number of SelectRx members increased by 17% over the prior year, contributing to the rise in medication and fulfillment costs[216]. Revenue and Income - Total revenue for the three months ended December 31, 2025, was $537,102,000, a 12% increase from $481,069,000 in the prior year[203]. - Pharmacy revenue increased by 26% to $227,209,000 for the three months ended December 31, 2025, primarily due to a 17% increase in members[207]. - Operating income for the three months ended December 31, 2025, was $75,311,000, representing a 6% increase from $70,940,000 in the prior year[203]. - Net income for the three months ended December 31, 2025, was $69,293,000, a 30% increase from $53,236,000 in the prior year[203]. - Total consolidated revenue for the three months ended December 31, 2025, was $537.1 million, an increase from $481.1 million in the same period of 2024, representing a year-over-year growth of approximately 11.7%[241][247]. Expenses and Costs - Cost of goods sold for pharmacy revenue increased by 31% to $205,194,000 for the three months ended December 31, 2025, mainly due to a $47.2 million rise in medication costs[214]. - Marketing and advertising expenses increased by $7.3 million, or 7%, for the three months ended December 31, 2025, primarily due to a $5.8 million increase in lead costs[218]. - Selling, general, and administrative expenses decreased by $6.1 million, or 14%, for the three months ended December 31, 2025, primarily due to a $6.3 million decrease in corporate development costs[222]. - Cost of commissions and other services revenue increased by 2% to $103,034,000 for the three months ended December 31, 2025, primarily due to a rise in compensation costs[211]. Segment Performance - Healthcare Services segment generated external revenue of $259.2 million for the three months ended December 31, 2025, up from $253.8 million in the same period of 2024, reflecting a growth of approximately 2.7%[241][247]. - Senior segment reported external revenue of $230.4 million for the three months ended December 31, 2025, compared to $183.3 million in the same period of 2024, marking a significant increase of about 25.7%[241][247]. - Revenue from Healthcare Services increased by $112.9 million, or 33%, to $452.0 million for the six months ended December 31, 2025, driven by a 17% increase in SelectRx members[268]. - Revenue from Senior decreased by $28.0 million, or 8%, to $320.5 million for the six months ended December 31, 2025, primarily due to a $24.1 million decrease in commission revenue[269]. Financial Position and Debt - The Company had total debt obligations of $405.8 million as of December 31, 2025, up from $385.1 million as of June 30, 2025[286]. - The Company entered into a new $415.0 million credit facility on January 8, 2026, which includes a $325.0 million senior secured term loan and a revolving credit facility of up to $90.0 million[284]. - As of December 31, 2025, the Company had $23.3 million in cash, cash equivalents, and restricted cash, down from $37.1 million as of June 30, 2025[287]. Adjusted EBITDA - Adjusted EBITDA for the three months ended December 31, 2025, was $84.7 million, compared to $87.5 million for the same period in 2024[234]. - Adjusted Segment EBITDA for the three months ended December 31, 2025, was $108.9 million, compared to $110.2 million for the same period in 2024, indicating a slight decrease of about 1.2%[242][248]. - Adjusted EBITDA from Senior for the six months ended December 31, 2025, was $81.4 million, a decrease of $26.8 million compared to the prior year[274]. - Adjusted EBITDA from Healthcare Services increased to $8.1 million for the six months ended December 31, 2025, reflecting a $112.9 million revenue increase, despite a $111.8 million rise in cost of goods sold[275]. Impairments and Charges - The Company recognized an impairment charge of $1.0 million during the three months ended December 31, 2025, representing a full write-off of its equity-method investment[246][257]. Interest and Tax Expenses - Interest expense decreased by $12.1 million, or 51%, for the three months ended December 31, 2025, primarily driven by a lower cost of capital following the completion of the securitization transaction[227]. - Income tax expense for the three months ended December 31, 2025, was $13.7 million, with an effective tax rate of 16.5%[229].

SelectQuote (NYSE:SLQT) Q2 2026 Earnings call February 05, 2026 08:00 AM ET Speaker5Welcome to SelectQuote's second quarter earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star 1 again. It is now my pleasure to introdu ...

2nd Quarter Fiscal 2026 Earnings Presentation February 5, 2026 | We shop. You save. Disclaimer Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "could," "predict," "potential," "believe," "will likely result," "expect," "continu ...

Exhibit 99.1 SelectQuote, Inc. Reports Second Quarter of Fiscal Year 2026 Results Second Quarter of Fiscal Year 2026 – Consolidated Earnings Highlights Fiscal Year 2026 Guidance Ranges: Second Quarter Fiscal Year 2026 – Segment Highlights Senior Healthcare Services Life OVERLAND PARK, Kan., February 5, 2026--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the second quarter of fiscal year 2026 of $537.1 million compared to consolidated revenue for the second quarter of fisc ...

Core Insights - The stock market has experienced significant volatility in January, particularly affecting major healthcare insurers due to news regarding Medicare reimbursement rates [1] Group 1: Industry Impact - Major healthcare insurers, including UnitedHealth Group, have seen their stock prices shaken by recent developments in Medicare reimbursement rates [1] Group 2: Analyst Background - Gary Alexander, with extensive experience in technology and healthcare sectors, has been a contributor to Seeking Alpha since 2017 and has provided insights on industry trends [1]

Financing Overview - SelectQuote has secured $415 million in financing, which includes a $325 million term loan from Pathlight Capital and a $90 million credit facility from UMB Bank [1] - The refinancing extends the company's term debt maturity to January 2031 and enhances liquidity for ongoing operations [1] Credit Facility Details - The revolving credit facility has been increased to $90 million during peak periods, up from $72 million previously [2] - The new term loan features lower principal amortization and offers greater investment flexibility compared to prior term debt [2] Management Commentary - CEO Tim Danker expressed satisfaction with the new financing agreement, highlighting it as a significant milestone for optimizing the capital structure and supporting growth in senior health insurance and healthcare services [3] - The new facility provides a modestly lower cost of capital and includes provisions for potential future interest rate reductions of up to 100 basis points [3] Business Model Confidence - The refinancing reflects lender confidence in SelectQuote's business model, supported by approximately $1 billion in commissions receivable and increasing cash generation from the SelectRx pharmacy and healthcare services division [4] - CFO Ryan Clement noted that the financing validates the business model and strengthens liquidity and financial flexibility for strategic priorities [5] Previous Investments - In February, SelectQuote received a $350 million investment from funds managed by Bain Capital, Morgan Stanley Private Credit, and Newlight Partners [5]